LAMEA Advanced Therapy Medicinal Products CDMO Market Size, Share & Industry Trends Analysis Report By Indication, By Product (Gene Therapy, Cell Therapy, and Tissue Engineered & Others), By Phase (Phase I, Phase II, Phase III, and Phase IV), By Country and Growth Forecast, 2022 - 2028
Special Offering: Industry Insights | Market Trends | Highest number of Tables | 24/7 Analyst Support
Get in-depth analysis of the COVID-19 impact on the LAMEA Advanced Therapy Medicinal Products CDMO Market
Market Report Description
The Latin America, Middle East and Africa Advanced Therapy Medicinal Products CDMO Market would witness market growth of 18.9% CAGR during the forecast period (2022-2028).
The support that CDMOs provide in achieving deadlines and overcoming challenges, such the brittleness of large molecule-based active compounds, in the early stages of drug development, is driving their growth. There are many cutting-edge methods that have been created to address the fragility and complexity problems with ATMPs.
For instance, buffer usage and encapsulation strategies safeguard large molecules by encouraging their stability. Approximately 350 million people globally are afflicted by the 7,000 identified rare diseases. The majority of rare diseases are genetically based, and between 65 and 75 percent of rare disorders first manifest in childhood.
Only 5% of rare diseases have a therapy that works. As a result, there is a significant unmet need in this field, which is influencing pharmaceutical and biopharmaceutical companies as well as research organizations to increase their R&D. This is especially benefitting the advanced therapy medicinal products CDMO market.
Efforts are being made to raise the awareness of health hazards posed by diseases like cancer in many African countries. These efforts were further reinforced by the Brazzaville Declaration in the WHO African Region. The signatories vowed, among other things, to create prevention and control plans, improve their health systems to lessen the burden of NCDs, and raise money to battle these illnesses. These efforts would help in supporting their national health information systems in producing data on NCDs and their risk factors. However, this direction is still making slow progress. As per latest information, only a few of the 46 countries in the African region that participated in a WHO study had functional cancer policies, strategies, or action plans. Therefore, during the projected period, these factors are probably going to boost the advanced therapy medicinal products CDMO market.
The Brazil market dominated the LAMEA Advanced Therapy Medicinal Products CDMO Market by Country in 2021, and would continue to be a dominant market till 2028; thereby, achieving a market value of $123.4 million by 2028. The Argentina market is exhibiting a CAGR of 19.6% during (2022 - 2028). Additionally, The UAE market would display a CAGR of 18.6% during (2022 - 2028).
Based on Indication, the market is segmented into Oncology, Cardiology, Central Nervous System & Musculoskeletal, Infectious Disease, Dermatology, Endocrine, Metabolic, Genetic, Immunology & Inflammation, Ophthalmology, Hematology, Gastroenterology, and Others. Based on Product, the market is segmented into Gene Therapy, Cell Therapy, and Tissue Engineered & Others. Based on Phase, the market is segmented into Phase I, Phase II, Phase III, and Phase IV. Based on countries, the market is segmented into Brazil, Argentina, UAE, Saudi Arabia, South Africa, Nigeria, and Rest of LAMEA.
Free Valuable Insights: The Global Advanced Therapy Medicinal Products CDMO Market is Predict to reach $11.9 Billion by 2028, at a CAGR of 16.3%
The market research report covers the analysis of key stake holders of the market. Key companies profiled in the report include Thermo Fisher Scientific, Inc. (Patheon, Inc.), AGC Biologics, Inc. (AGC, Inc.), Catalent, Inc., Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation), WuXi AppTec Co., Ltd. (WuXi Advanced Therapies), Lonza Group AG, Celonic AG (JRS PHARMA GmbH & Co. KG), Rentschler Biopharma SE, and Bio Elpida (Polyplus-transfection SA.)
Scope of the Study
Market Segments Covered in the Report:
- Central Nervous System & Musculoskeletal
- Infectious Disease
- Endocrine, Metabolic, Genetic
- Immunology & Inflammation
- Gene Therapy
- Cell Therapy
- Tissue Engineered & Others
- Phase I
- Phase II
- Phase III
- Phase IV
- Saudi Arabia
- South Africa
- Rest of LAMEA
Key Market Players
List of Companies Profiled in the Report:
- Thermo Fisher Scientific, Inc. (Patheon, Inc.)
- AGC Biologics, Inc. (AGC, Inc.)
- Catalent, Inc.
- Minaris Regenerative Medicine GmbH (Resonac Holdings Corporation)
- WuXi AppTec Co., Ltd. (WuXi Advanced Therapies)
- Lonza Group AG
- Celonic AG (JRS PHARMA GmbH & Co. KG)
- Rentschler Biopharma SE
- Bio Elpida (Polyplus-transfection SA.)
Unique Offerings from KBV Research
- Exhaustive coverage
- The highest number of Market tables and figures
- Subscription-based model available
- Guaranteed best price
- Assured post sales research support with 10% customization free
Global Advanced Therapy Medicinal Products CDMO Market Report 2022-2028
North America Advanced Therapy Medicinal Products CDMO Market Report 2022-2028
Asia Pacific Advanced Therapy Medicinal Products CDMO Market Report 2022-2028
Europe Advanced Therapy Medicinal Products CDMO Market Report 2022-2028